Read Larry Connors' blog – Short Term Trading Strategies
Amgen's announcement relates to results from the Phase III PRIME '203' trial evaluating Vectibix (panitumumab) administered in combination with FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) as a first-line treatment for metastatic colorectal cancer (CRC). Median overall survival for Vectibix was 23.9 months compared to 19.7 months for patients treated with FOLFOX alone. Overall survival was the PRIME study's secondary endpoint and the difference of 4.2 months failed to meet statistical significance (p=0.072).
Vectibix is a recombinant, fully human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Vectibix is approved in the US and EU as a monotherapy for the treatment of patients with EGFR-expressing metastatic CRC after disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan-containing chemotherapy regimens. Currently Vectibix is in several Phase III trials investigating its use in other lines of metastatic CRC therapy, as well as metastatic head and neck cancer.
CRC is the third most common type of cancer and Datamonitor forecasts its incidence in the seven major pharmaceutical markets to be more than 478,000 in 2009. Cure is not possible for most patients with the disease, but chemotherapy with or without molecular targeted therapies may be used to improve symptoms and prolong life.
Previous PRIME study results for Vectibix presented at the European Society for Medical Oncology Congress in September 2009 were encouraging. Vectibix met its primary endpoint of increasing progression-free survival when administered in combination with FOLFOX in the PRIME study, and in the separate Phase III '181' trial, progression-free survival was improved when Vectibix was combined with FOLFIRI (leucovorin, 5-fluorouracil, irinotecan).
If approved for first-line metastatic CRC, Vectibix will be competing with Erbitux (cetuximab; Eli Lilly/Merck Serono/Bristol-Myers Squibb): another anti-EGFR monoclonal antibody. Results from the recent Phase III CRYSTAL trial evaluating Erbitux in combination with FOLFIRI (folinic acid, fluorouracil, irinotecan) demonstrated that patients in the Erbitux arm had a significantly improved overall survival (p=0.0094) compared to those receiving chemotherapy alone.
In the CRYSTAL trial, Erbitux improved median overall survival by 3.5 months. Despite not being statistically significant, Amgen will be encouraged by the median overall survival improvement of 4.2 months in the most recent PRIME trial. The company should consider further trials to further explore the drug's impact on survival and increase its chances of effectively competing with Erbitux.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
